|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TRIM23 |
Gene summary for TRIM23 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TRIM23 | Gene ID | 373 |
| Gene name | tripartite motif containing 23 | |
| Gene Alias | ARD1 | |
| Cytomap | 5q12.3 | |
| Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | P36406 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 373 | TRIM23 | LZE24T | Human | Esophagus | ESCC | 1.52e-07 | 1.16e-01 | 0.0596 |
| 373 | TRIM23 | LZE6T | Human | Esophagus | ESCC | 1.28e-02 | 1.12e-01 | 0.0845 |
| 373 | TRIM23 | P1T-E | Human | Esophagus | ESCC | 1.76e-02 | 1.19e-01 | 0.0875 |
| 373 | TRIM23 | P2T-E | Human | Esophagus | ESCC | 1.87e-10 | 2.13e-01 | 0.1177 |
| 373 | TRIM23 | P4T-E | Human | Esophagus | ESCC | 2.22e-11 | 1.09e-01 | 0.1323 |
| 373 | TRIM23 | P5T-E | Human | Esophagus | ESCC | 3.43e-07 | 5.00e-02 | 0.1327 |
| 373 | TRIM23 | P8T-E | Human | Esophagus | ESCC | 2.27e-09 | 1.20e-01 | 0.0889 |
| 373 | TRIM23 | P9T-E | Human | Esophagus | ESCC | 2.60e-05 | 8.82e-02 | 0.1131 |
| 373 | TRIM23 | P10T-E | Human | Esophagus | ESCC | 4.33e-06 | 1.03e-01 | 0.116 |
| 373 | TRIM23 | P12T-E | Human | Esophagus | ESCC | 8.85e-04 | 1.51e-01 | 0.1122 |
| 373 | TRIM23 | P15T-E | Human | Esophagus | ESCC | 4.27e-05 | 1.08e-01 | 0.1149 |
| 373 | TRIM23 | P16T-E | Human | Esophagus | ESCC | 1.45e-13 | 2.38e-01 | 0.1153 |
| 373 | TRIM23 | P20T-E | Human | Esophagus | ESCC | 5.46e-13 | 1.51e-01 | 0.1124 |
| 373 | TRIM23 | P21T-E | Human | Esophagus | ESCC | 2.67e-06 | 5.35e-02 | 0.1617 |
| 373 | TRIM23 | P22T-E | Human | Esophagus | ESCC | 4.98e-11 | 7.99e-02 | 0.1236 |
| 373 | TRIM23 | P23T-E | Human | Esophagus | ESCC | 3.38e-05 | 1.15e-01 | 0.108 |
| 373 | TRIM23 | P24T-E | Human | Esophagus | ESCC | 7.57e-05 | 3.07e-02 | 0.1287 |
| 373 | TRIM23 | P26T-E | Human | Esophagus | ESCC | 1.60e-18 | 1.32e-01 | 0.1276 |
| 373 | TRIM23 | P27T-E | Human | Esophagus | ESCC | 1.63e-03 | 6.33e-02 | 0.1055 |
| 373 | TRIM23 | P30T-E | Human | Esophagus | ESCC | 3.35e-10 | 1.89e-01 | 0.137 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TRIM23 | SNV | Missense_Mutation | c.959N>T | p.Trp320Leu | p.W320L | P36406 | protein_coding | tolerated(0.68) | benign(0) | TCGA-AC-A23C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | chemo | CR | |
| TRIM23 | SNV | Missense_Mutation | rs371065655 | c.1646N>A | p.Arg549Gln | p.R549Q | P36406 | protein_coding | tolerated(0.74) | possibly_damaging(0.833) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TRIM23 | SNV | Missense_Mutation | c.232N>C | p.Val78Leu | p.V78L | P36406 | protein_coding | tolerated(0.32) | benign(0.001) | TCGA-AN-A0AR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TRIM23 | SNV | Missense_Mutation | c.640N>G | p.His214Asp | p.H214D | P36406 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-C8-A27B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
| TRIM23 | SNV | Missense_Mutation | c.1417C>G | p.Gln473Glu | p.Q473E | P36406 | protein_coding | deleterious(0.01) | probably_damaging(0.929) | TCGA-E2-A159-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| TRIM23 | SNV | Missense_Mutation | c.1516N>T | p.Ala506Ser | p.A506S | P36406 | protein_coding | tolerated(0.05) | probably_damaging(0.993) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | |
| TRIM23 | SNV | Missense_Mutation | c.1516N>T | p.Ala506Ser | p.A506S | P36406 | protein_coding | tolerated(0.05) | probably_damaging(0.993) | TCGA-C5-A3HL-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TRIM23 | SNV | Missense_Mutation | c.268N>G | p.Lys90Glu | p.K90E | P36406 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TRIM23 | SNV | Missense_Mutation | c.275N>T | p.Asn92Ile | p.N92I | P36406 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| TRIM23 | SNV | Missense_Mutation | rs752496483 | c.866G>A | p.Arg289Gln | p.R289Q | P36406 | protein_coding | tolerated(0.07) | benign(0.246) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |